HOOD vs NU

HOOD exhibits significant fundamental weakness with a Piotroski F-Score of 3/9, indicating poor financial health. The stock is trading at a massive premium ($82.07) compared to its Graham Number ($21.63) and Intrinsic Value ($14.35), suggesting severe overvaluation. While revenue growth remains strong at 26.5%, the negative YoY earnings growth (-34.5%) and aggressive insider selling, particularly by the CEO, create a high-risk profile. The disconnect between analyst optimism and deterministic value metrics is stark.

NU presents a stark contrast between traditional accounting health and explosive growth metrics, highlighted by a weak Piotroski F-Score of 2/9. While the deterministic health score is poor, the company's operational performance is exceptional, featuring 60.9% YoY earnings growth and a highly attractive PEG ratio of 0.85. The current price of $14.48 trades at a significant premium to the Graham Number ($5.51) but remains below the growth-based intrinsic value of $17.11. Ultimately, the strong ROE of 30.28% and aggressive scaling suggest a high-growth fintech trajectory that outweighs short-term deterministic health warnings.